Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate‐stage Hepatocellular Carcinoma: A Multicenter Retrospective Study
Yitao Zheng,Yanjun Xiang,Hongqi Shi,Zhuoqun Lin,Shuqun Cheng,Jiuting Zhu
DOI: https://doi.org/10.2147/jhc.s461630
2024-06-13
Journal of Hepatocellular Carcinoma
Abstract:Yitao Zheng, 1, 2, &ast Yanjun Xiang, 3, &ast Hongqi Shi, 2, &ast Zhuoqun Lin, 2 Shuqun Cheng, 3 Jiuting Zhu 1 1 Department of Pancreatic and Gastrointestinal Surgery Division, Ningbo No.2 Hospital, Ningbo, People's Republic of China; 2 Department of Hepatological Surgery, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China; 3 Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shuqun Cheng, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, 225 Changhai Road, Shanghai, 200433, People's Republic of China, Email Jiuting Zhu, Department of Pancreatic and Gastrointestinal Surgery Division, Ningbo No.2 Hospital, 41 Xibei Street, Ningbo, People's Republic of China, Email Purpose: Combining transarterial chemoembolization (TACE) with systemic therapy has shown significant efficacy for intermediate-stage hepatocellular carcinoma (HCC) patients. This study aimed to validate the therapeutic efficacy of TACE combined with atezolizumab and bevacizumab (TACE + Atez/Bev) compared to TACE alone. Methods: A retrospective study was conducted across three centers in China, encompassing 155 patients at the intermediate-stage of HCC. Propensity Score Matching (PSM) was used to minimize selection bias, with a ratio of 1:1. Primary outcomes were TACE-specific Progression-Free Survival (PFS) and Overall Survival (OS). Objective Response Rate (ORR) and Disease Control Rate (DCR) were assessed based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Adverse events (AEs) related to treatment were analyzed to evaluate safety. Results: Before PSM, the TACE + Atez/Bev group demonstrated extended median OS (not reached vs 20.3 months, P = 0.004) and PFS (20.0 months vs 9.8 months, P = 0.029) compared to the TACE-alone group. The TACE + Atez/Bev group also had a higher ORR (60.9% vs 41.3%, P = 0.026) and DCR (89.1% vs 58.7%, P < 0.001) than the TACE-alone group. After applying the PSM, the study included 42 pairs of patients. Compared to the TACE-alone group, the combination therapy group also showed significantly longer median OS (not reached vs 21.4 months, P = 0.008) and PFS (21.7 vs 9.7 months, P = 0.009). The combination therapy group also had a higher ORR (66.7% vs 38.1%, P = 0.009) and DCR (92.9% vs 57.1%, P < 0.001). AEs in the combination therapy group were mostly manageable, with the most common being elevated liver transaminase. Conclusion: In treating intermediate-stage HCC, the survival benefit of combining TACE with atezolizumab and bevacizumab was significantly higher than TACE alone, and the treatment was well-tolerated. Keywords: atezolizumab, bevacizumab, hepatocellular carcinoma, prognosis, transarterial chemoembolization Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent cancer and the third highest contributor to cancer-related fatalities globally. 1 The early stages of HCC often exhibit no symptoms, leading to over half of the patients being diagnosed at intermediate to advanced stages, hence missing the opportunity for radical resection. 2,3 Patients with intermediate-stage HCC fall under the category of Barcelona Clinic Liver Cancer (BCLC) stage B. 1 Transarterial chemoembolization (TACE) is the recommended standard treatment for these patients according to multiple guidelines. 4–7 However, the effectiveness of TACE alone is often limited due to the high heterogeneity of intermediate-stage liver cancer. 8,9 The latest BCLC guidelines have been revised to recommend systemic therapy for some patients in stage B, in addition to TACE. 10 The TACTICS trial has successfully demonstrated that the combined or sequential use of sorafenib and TACE can provide significant clinical benefits in TACE-specific Progression-Free Survival (PFS), 11 and an increasing number of studies have found that TACE combined with other systemic therapies can improve the prognosis of HCC patients. 12–15 TACE induces tumor necrosis by embolizing the tumor-supplying arteries, leading to an elevated expression of the vascular endothelial growth factor (VEGF). 16 Furthermore, TACE triggers an increase in the release of tumor neoantigens, thereby boosting immune activation and recognition. 17 Atezolizumab and bevacizumab, respectively a PD-L1 inhibitor and an anti-angiogenic drug, are recommended as the first-line systemic treatment for patients with inte -Abstract Truncated-
oncology